Tevogen Logo Notified.png
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
September 24, 2024 11:09 ET | Tevogen Bio Inc
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Custom Antibody Services Market to Reach $1.4 Billion, Globally, by 2033 at 8.7% CAGR: Allied Market Research
September 24, 2024 09:36 ET | Allied Analytics LLP
Wilmington, Delaware, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Custom Antibody Services Market by Service (Antibody Development, Antibody Production and...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
September 24, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Transparency Market Research
Nuclear Medicine Market Projected Growth at 9.2% CAGR to Reach USD 11.4 billion by 2031 | Exclusive Research Report by Transparency Market Research Inc.
September 23, 2024 06:58 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 23, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global nuclear...
finacialnews-logo-final-01 (2).png
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024 09:00 ET | FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
Keck Graduate Instit
Keck Graduate Institute Awarded $750,000 Grant from the Department of Energy to Study Low-Level Radiation Effects
September 19, 2024 14:34 ET | Keck Graduate Institute
Claremont, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Keck Graduate Institute (KGI), a member of The Claremont Colleges, has been awarded a significant grant from the Department of Energy to investigate...
AIMLogo.jpg
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
September 19, 2024 08:00 ET | AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
logo.jpg
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors
September 19, 2024 08:00 ET | Helsinn Healthcare S.A.
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of...
logo (1).png
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
September 19, 2024 01:00 ET | Vidac Pharma Holding PLC
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
plus_logo.png
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
September 18, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting